SLIDESHOW: Shoppers Drug Mart debuts aging-focused Wellwise pilot
TORONTO, Ontario — In an effort to connect with Canada’s aging population, Shoppers Drug Mart this week will unveil its new pilot retail experience in Toronto’s Leaside neighborhood. The Wellwise store pilot will get a grand opening and ribbon-cutting ceremony on Saturday, Sept. 23.
With more Canadians over 65 years of age than under 15 years of age, Shoppers Drug Mart said the pilot focuses on giving patients control over the way they age in an environment that it said eschews the clinical experience of DME stores for a focus on aging gracefully. The store concentrates in there areas — experience, empowering and education (the store has a dietitian on staff).
The standalone, 3,500-sq.-ft. store’s inventory will encompass such categories as wellness (aromatherapy), recovery (first aid), mobility, home comfort, tools and gadgets, personal care and active living, which includes products for yoga, compression and light weights.
“We are going to change the conversation about how people age,” Shoppers Drug Mart SVP healthcare business Theresa Firestone told Drug Store News. “People don’t generally look forward to that part of life [and] this is an opportunity for people to look forward to that part of life, because you can age powerfully, you can take control and there are lots of ways you can be active and enjoy life.”
Leading hearing aid manufacturer Starkey launches complete ear care line
MINNEAPOLIS — Starkey Hearing Technologies on Tuesday announced the availability of its new Ear Health product line, including solutions for earwax, earaches, itchy ears, dry ears and for protecting ears from damaging sounds.
Starkey Hearing is already a well-known brand among prescription-only hearing aid products. This move creates a brand resonance for Starkey in the ear care aisle, which may see more hearing aid manufacturers enter the space as hearing aids indicated for mild to moderate hearing loss migrate into OTC sets.
“[Starkey] Ear Health products were designed to give consumers an easy way to take care of their ears," stated Chris McCormick, chief marketing officer Starkey Hearing Technologies. "It is our hope that because of these products, we will see more people take an earlier and more proactive approach to ear and hearing health, which will in turn lead to overall improved health and wellness.”
Starkey's Ear Health products were developed by consulting audiologists and hearing health professionals to address consumers’ top needs for maintaining ear health. As a leading U.S. hearing aid brand, the complete Ear Health line gives consumers easier, one-stop ear healthcare.
“With a dedicated website, attention-grabbing packaging and the Starkey Hearing Technologies name, consumers can now buy ear health products from the company that audiologists and consumers trust,” McCormick added.
Foundation Consumer Healthcare among buyers of Teva’s women’s health brands
JERUSALEM — Teva has made two separate sales from its global women’s health business in an effort to repay term loan debt. The move follows its sale last week of its Paragard IUD.
“Today’s announcement, coupled with the recent announcement of the sale of Paragard for $1.1 billion, demonstrate Teva’s commitment to delivering on our promise to generate net proceeds of at least $2 billion from the divestiture of non-core assets,” interim Teva CEO Dr. Yitzhak Peterburg said. “With these initial divestitures we have exceeded expectations, leveraging the tremendous value we have built within Teva’s specialty business.”
The company has $675 million all-cash deal with Foundation Consumer Healthcare, which will be acquiring Plan B One-Step emergency contraception, as well as other emergency contraceptive brands Take Action, Aftera and Next Choice One Dose. The drugs had combined U.S. sales of $140 million for the full-year 2016.
Teva also has entered a deal with CVC Capital Partners, which is paying $703 million in cash for a portfolio of produts for menopause, fertility and osteoporosis. The products, all of which are sold outside the United States, include Ovaleap, Zoely, Seasonique, Colpotrophine and Actonel, among others. The products being acquired by CVC Capital Partners had combined sales of $258 million in 2016, the company said.
“Teva is extremely pleased to enter into these agreements with CVC Capital Partners and Foundation Consumer Healthcare, which progress our ability to repay term loan debt while also providing a clear path forward for these important products to continue to be available to women throughout the world,” Teva interim Peterburg said.